A phase II randomised trial of biomarkers to assess (dose-) response in patients with metastatic castration resistant prostate cancer treated with radium-223

Trial Profile

A phase II randomised trial of biomarkers to assess (dose-) response in patients with metastatic castration resistant prostate cancer treated with radium-223

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms REASURE
  • Sponsors Bayer HealthCare Pharmaceuticals Inc.
  • Most Recent Events

    • 22 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 May 2017 Planned End Date changed from 30 Nov 2017 to 1 Dec 2018.
    • 08 Feb 2016 Planned End Date changed to 30 Nov 2017 as per United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top